Interestingly, in the latter, this treatment reprogrammed the tumour microenvironment, rendering the tumour responsive to anti-CTLA-4 immunotherapy, a significant finding for immunoresistant cancers [170]. The gene discussed is CTLA4; the disease is neoplasm.